Source of the article: Siyu MedTechReprint Requirements: Please indicate the source of the article at the beginning of the text, and it can be reprinted directly.
On January 5, 2024, the China Securities Regulatory Commission (CSRC) disclosed on its official website that Shenzhen Certainn Technology Co., Ltd. (referred to as "Moptim") had initiated the filing for IPO tutoring. The tutoring institution is China Merchants Securities, and the dispatched institution is the Shenzhen CSRC Bureau.
It is reported that the company isIn ChinaThe only enterprise with intellectual property rights for ophthalmic OCT tomography scanners, integrated photoelectric colposcopes, and vision screening instruments.。
# About Moptim
Shenzhen Certainn Technology Co., Ltd. (referred to as "Moptim") was established in 2003.CompanyCommitted to the industrialization of ophthalmic Optical Coherence Tomography (OCT).In March 2022, the company received tens of millions of yuan in A+ round financing from Baidu Ventures.
Moptim focuses onOphthalmic Diagnosis, Ophthalmic Surgery, Refraction ExaminationThree major core细分 fields of ophthalmology, including products such as Ophthalmic Optical Coherence Tomography (OCT), Ophthalmic Optical Biometer, Ophthalmic Surgical Microscope, Slit Lamp Microscope, Handheld Vision Screener, Home Refractometer, and Intelligent Electronic Vision Chart.
▲Company Products (from Official WeChat)
OCT (Optical Coherence Tomography), as a high-end medical device in ophthalmology, is completely reliant on imports and is expensive.After a long period of dedicated research and development and industrialization exploration,At the end of 2008, Moptim obtained the first OCT registration certificate for domestically produced equipment in China, successfully breaking foreign monopolies and achieving the industrialization of OCT devices. It became the first approved ophthalmic OCT medical equipment enterprise in China.。Immediately following, Moptim launched China's first Doppler OCT angiography and the world’s first optical biometer for ophthalmology based on swept-source OCT technology.▲Moptim's earliest OCT model, developed in 2003 (from the official website)After more than a decade of industry development, Moptim has become a leader in the field of domestically produced ophthalmic medical devices in China, with its products and solutions covering over 8,000 medical institutions worldwide. In recent years, the increasing demand for biometers and myopia prevention and control equipment has gradually become a strong new growth point for the company.At the same time, Moptim has been actively expanding overseas markets and is one of the earliest ophthalmic medical device companies in China to establish a presence in international markets. It has currently built sales channels in more than 50 countries and regions, with products covering areas such as Europe, South America, and the Asia-Pacific region.As a collaborative research and development base of Tsinghua University's Shenzhen Graduate School, the company's technical and talent backbone originates from Tsinghua University. With the united efforts of this high-quality and youthful R&D team, the technology and products have maintained rapid development.At the international leading level in core aspects such as OCT core algorithms and optical design.MoptimSince its establishment, it has been closely cooperating and exchanging technology with Zhongshan Ophthalmic Center of Sun Yat-sen University, Shenzhen Eye Hospital, Peking University Shenzhen Hospital, and other universities and clinical medical institutions. It now owns 179 authorized patents, including 11 PCT patents.# Expand AI Ophthalmic Medical Device ServicesOphthalmic diseases are the third largest category of conditions affecting quality of life, following tumors and cardiovascular/cerebrovascular diseases.Traditionally, "difficulty in taking images" and "difficulty in reading images" have been the pain points in grassroots fundus screening. In this context, the application of AI in ophthalmology has gradually developed. Using artificial intelligence to analyze fundus images enables rapid screening for fundus diseases, such as common cataracts and diabetic retinopathy, achieving the goal of early screening, early prevention, and early treatment.In 2020, Moptim collaborated with Ping An Smart City, achieving breakthrough accomplishments in the fields of intelligent healthcare for early disease screening and AI-assisted diagnosis, successfully developing"OCT-AI": An Intelligent Ophthalmic OCT Screening System Combining China-Made OCT and AIThis system has four AI functions: OCT image quality control, retinal disease screening, automatic detection of retinal lesions, and OCT image quality enhancement.In addition, in February 2023,Moptim Announces Partnership as One of the First Ecosystem Collaborators of Baidu's ERNIE Bot.Moptim will apply Baidu's leading intelligent dialogue technology achievements in the field of ophthalmic medical devices. This move marks that Moptim is the first to gain the support of leading AI technology, and also marksThe First Landing of Conversational Language Model Technology in Ophthalmic Medical Scenarios in China。Editor-in-Chief | Zhao Qing Reviewed by | Yi He
